Q-omics provides the consensus-scored ORAI2 profile across patient tissues and cancer cell-line models. ORAI2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ORAI2 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ORAI2 RNA expression shows 18,570 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, LUAD, and KIRP as cancer lineages where ORAI2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ORAI2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ORAI2 survival associations across molecular data types. ORAI2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ORAI2 RNA expression–survival associations across cancer types. High ORAI2 expression shows unfavorable associations in UVM, MESO, LGG, LUSC and KICH, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ORAI2 RNA expression.
This table summarizes ORAI2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ORAI2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ORAI2 shows lower tumor expression in KICH and higher tumor expression in LUAD, KIRP, HNSC, BRCA and STAD. The LUAD box plot shows higher ORAI2 RNA expression in tumor versus normal tissue (log2 FC = +0.842, t-test p < 0.001).
This table shows molecular features associated with ORAI2 in patient tissues and cancer cell lines. In patient samples, ORAI2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ORAI2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
